FDA approves Impax's AB rated generic Concerta Extended-Release Tablets CII

Company expects to launch by the end of the year.

Impax Laboratories has received an AB therapeutic equivalent rating and final FDA approval on its Abbreviated New Drug Application (ANDA) for a generic version of Concerta (methylphenidate hydrochloride) Extended-Release tablets USP CII, 18, 27, 36 and 54 mg.

FDA approves Impax's AB rated generic Concerta Extended-Release Tablets CII

"Approval of our AB-rated generic version of Concerta further demonstrates the capabilities of Impax's R&D organization," said Paul Bisaro, President and Chief Executive Officer of Impax. "We are preparing for launch including working to secure API quota and currently expect to launch by the end of this year. As a result, we don't anticipate sales of generic Concerta to meaningfully impact our earnings in 2017."

Methylphenidate hydrochloride extended-release tablets had US sales of approximately $1.8 billion, according to IMS Health for the 12 months ending May 2017.

Methylphenidate hydrochloride extended-release tablets, are indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children 6 years of age and older, adolescents, and adults up to the age of 65.

Read More



Other news in “Market News”

CPhI Worldwide Pharma Awards finalists unveiled

CPhI Worldwide Pharma Awards finalists unveiled 

22 Sep 2017
Highly potent APIs - can your CMO handle them?

Highly potent APIs - can your CMO handle them? 

22 Sep 2017
Ardena acquisition will support sponsors with bioanalytical and drug discovery services

Ardena acquisition will support sponsors with bioanalytical and drug discovery services 

21 Sep 2017